Eli Lilly and Company CEDEAR logo

Eli Lilly and Company CEDEAR (LLYD)

Market Closed
5 Jun, 20:00
BCBA BCBA
$
21. 02
+0.15
+0.7187%
$
- Market Cap
104.2 P/E Ratio
0.05% Div Yield
4,559 Volume
6.64 Eps
$ 20.87
Previous Close
Add Transaction
Day Range
20.87 21.66
Year Range
11.2 21.72
Want to track LLYD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LLYD closed Friday higher at $21.02, an increase of 0.7187% from Thursday's close, completing a monthly increase of 19.7721% or $3.47. Over the past 12 months, LLYD stock gained 5.7344%.
LLYD is not paying dividends to its shareholders.
The last earnings report, released on Apr 29, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Eli Lilly and Company CEDEAR has completed 2 stock splits, with the recent split occurring on Jan 24, 2024.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on BCBA (ARS).

LLYD Chart

Eli Lilly and Company CEDEAR (LLYD) FAQ

What is the stock price today?

The current price is $21.02.

On which exchange is it traded?

Eli Lilly and Company CEDEAR is listed on BCBA.

What is its stock symbol?

The ticker symbol is LLYD.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.05%.

What is its market cap?

As of today, no market cap data is available.

Has Eli Lilly and Company CEDEAR ever had a stock split?

Eli Lilly and Company CEDEAR had 2 splits and the recent split was on Jan 24, 2024.

Eli Lilly and Company CEDEAR Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. David A. Ricks CEO
BCBA Exchange
- ISIN
BR Country
50,000 Employees
- Last Dividend
- Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center, Indianapolis, IN, United States, 46285
Phone: 317 276 2000